Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.
Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.
Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.
Oncolytics Biotech (NASDAQ: ONCY) has released updated safety data for its immunotherapy drug pelareorep, showcasing favorable results across multiple gastrointestinal cancers. The analysis encompasses over 1,200 total patients, including more than 300 gastrointestinal cancer patients across 8 clinical studies.
The data confirms pelareorep's consistent safety profile, with most adverse events being Grade 1 and 2, including fever, chills, fatigue, and gastrointestinal symptoms. The therapy has been tested in combination with various treatments, including modified FOLFIRINOX for metastatic pancreatic cancer, and in multiple tumor types such as colorectal and anal cancer.
Oncolytics Biotech (NASDAQ:ONCY), a clinical-stage immunotherapy company focused on developing pelareorep, has announced its participation in two upcoming investor conferences in September 2025. CEO Jared Kelly will engage with institutional investors at the H.C. Wainwright 27th Annual Global Investment Conference on September 9-10 and the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11.
Both events will take place in New York City, with management conducting one-on-one meetings with investors. Interested parties can schedule meetings through conference representatives or by contacting the company directly.
Oncolytics Biotech (NASDAQ: ONCY) held its Annual General Meeting (AGM) on August 8, 2025, with 37.42% of outstanding shares represented. The company successfully elected eight directors to its board, with approval rates ranging from 80.45% to 91.64%. The highest approval was received by Jared Kelly (91.64%), while Jonathan Rigby received the lowest support (80.45%).
Shareholders also approved additional resolutions, including fixing the board size at eight members and appointing auditors. The meeting results demonstrate strong shareholder support for the company's governance structure.
Oncolytics Biotech (NASDAQ: ONCY) reported Q2 2025 financial results and outlined strategic plans for its immunotherapy drug pelareorep. The company reported a net loss of $6.2 million with $14.6 million in cash, projecting runway into Q1 2026.
Key developments include plans for a registration-enabling pivotal study in first-line metastatic pancreatic cancer (mPDAC), with start-up activities expected in Q4 2025. Clinical data showed impressive 21.9% two-year survival rate in mPDAC patients compared to 9.2% historical benchmark. The company appointed new CEO Jared Kelly and CBO Andrew Aromando, both experienced in successful biotech transactions.
Oncolytics demonstrated commitment to reducing dilution by terminating its At-the-Market and Equity Line of Credit facilities, and announced plans to delist from TSX while maintaining NASDAQ listing.
Oncolytics Biotech (NASDAQ: ONCY) has announced its voluntary delisting from the Toronto Stock Exchange (TSX), effective August 22, 2025. The company's shares will continue trading on the Nasdaq under the symbol "ONCY". This strategic decision comes as Oncolytics will cease to be a Foreign Private Issuer effective January 1, 2026.
The clinical-stage immunotherapy company, which develops pelareorep, made this decision based on several factors, including maintaining its Nasdaq listing, potential future U.S. re-domiciling plans, and cost efficiency considerations given its U.S. focus and shareholder base. Canadian shareholders will retain their ability to trade shares on Nasdaq through brokers with U.S.-registered affiliates.
Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage immunotherapy company focused on pelareorep development, has scheduled its 2025 Annual General Meeting for August 8, 2025, at 10:00 a.m. ET. The meeting will be held virtually, with CEO Jared Kelly providing a corporate update and discussing strategic milestones for 2025 after the formal shareholder voting.
The company will also release its second quarter 2025 financial results before market opening on the same day. Shareholders can access detailed voting information through the Management Information Circular dated June 18, 2025, available on the company's website and in securities filings.
Oncolytics Biotech (NASDAQ: ONCY) has initiated FDA discussions for a potential registration-enabled pivotal study of pelareorep in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC). The company plans to commence study activities by the end of 2025, focusing on a trial design that combines pelareorep with chemotherapy and potentially checkpoint inhibition.
The company aims to leverage its Fast Track and Orphan Drug designations in mPDAC, with overall survival as the primary endpoint. The strategy includes exploring an adaptive study design in collaboration with a third party, positioning Oncolytics for potential partnerships in GI oncology. Recent Key Opinion Leader feedback has validated pelareorep's ability to transform "cold" tumors into immunologically active ones, particularly in KRAS-mutated colorectal cancer.
Oncolytics Biotech (NASDAQ: ONCY) hosted a key opinion leader (KOL) webinar focusing on pelareorep's clinical data in pancreatic and gastrointestinal cancers. The event highlighted significant survival benefits demonstrated by pelareorep-based combinations in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) patients.
Key findings show that pelareorep combined with chemotherapy represents a promising treatment option for mPDAC patients. Translational data from multiple clinical trials validated pelareorep's mechanism of action, demonstrating tumor replication, chemokine expression stimulation, and correlation between tumor-infiltrating lymphocytes expansion and tumor size reduction.
Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage immunotherapy oncology company, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received formal confirmation from Nasdaq's Listing Qualifications Department on July 22, 2025.
After falling below the required $1.00 minimum bid price in February 2025, ONCY has maintained a closing bid price at or above $1.00 for 10 consecutive business days from July 8 through July 21, 2025. The company is now fully compliant with all Nasdaq listing standards and will continue trading on the Nasdaq Capital Market.
Oncolytics Biotech (NASDAQ: ONCY) presented comprehensive translational data demonstrating the effectiveness of its immunotherapy candidate pelareorep across multiple tumor types. The data, derived from the GOBLET and AWARE-1 studies, showed consistent immune activation signatures in pancreatic, gastrointestinal, and breast cancers.
Key findings revealed that pelareorep successfully converts 'cold' tumors to 'hot' by upregulating interferons and PD-L1, expanding tumor-infiltrating lymphocytes, and modifying the tumor microenvironment. The company expects additional translational data readouts next year and plans to provide an updated clinical timeline by the end of Q3 2025.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
